CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells.
TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法用于治疗人类血液系统恶性肿瘤,但其疗效受T细胞耗竭(TEX)限制。T细胞耗竭的发生伴随着中央记忆T细胞(TCM)减少,而TCM具有强抗肿瘤效力。一名白血病患者的TET2基因表达降低并实现完全缓解,该现象与TCM分化增加相关。本研究显示,TET2缺失会增加耗竭调节因子TOX和TOX2位点的染色质可及性,并提高TOX2表达。敲低TOX可增加TCM比例;但出乎意料的是,敲低TOX2会降低TCM比例并减少细胞增殖。与此一致,TOX2敲低后TCM基因特征降低,且TOX2可结合多个TCM基因启动子。因此,研究结果提示,与耗竭调节因子TOX不同,人TOX2可能促进CAR-T 细胞中央记忆分化。通过调节TOX2表达来辅助CAR-T 癌症治疗具有潜在应用价值。
Chimeric antigen receptor (CAR) T cell therapy is used in treating human hematological malignancies, but its efficacy is limited by T cell exhaustion (T EX ). T EX arises at the expense of central memory T cells (T CM ), which exhibit robust antitumor efficacy. Reduction of the TET2 gene led to increased T CM differentiation in a patient with leukemia who experienced a complete remission.
We show that loss of TET2 led to increased chromatin accessibility at exhaustion regulators TOX and TOX2, plus increased expression of TOX2. Knockdown of TOX increased the percentage of T CM .
However, unexpectedly, knockdown of TOX2 decreased T CM percentage and reduced proliferation. Consistently, a T CM gene signature was reduced in the TOX2 knockdown, and TOX2 bound to promoters of numerous T CM genes.
Our results thus suggest a role for human TOX2, in contrast to exhaustion regulator TOX, as a potentiator of central memory differentiation of CAR T cells, with plausible utility in CAR T cell cancer therapy via modulated TOX2 expression.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。